The cystic fibrosis therapeutics market is projected to grow from USD 19.5 billion in 2025 to USD 181.9 billion by 2035, at a CAGR of 25.0%. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) will dominate with a 47.3% market share, while oral will lead the route of administration segment with a 61.5% share.